Associate Professor and Director, Division of Gynecologic Oncology, University of Cincinnati College of Medicine
Obstetrics & Gynecology
Dr. Eric L. Eisenhauer, MD
|
|
Give Review
Eric Eisenhauer practices Obstetrics & Gynecology. He attended University of California San Diego School of Medicine. University of California San Diego School of Medicine is ranked 17 in research and 19 in primary care medicine He has 2 awards "Regional Top Doctor" and "CMS Meaningful Use Stage 1 Certification". Eric Eisenhauer is a published doctor. He published 38 publications, including: 'Predicting Inpatient Stay Lasting Two Midnights or More after Robotic Surgery for Endometrial Cancer.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Predicting Inpatient Stay Lasting Two Midnights or More after Robotic Surgery for Endometrial Cancer.
- Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated Cervical, vaginal, or vulvar cancer?
- Hereditary Cancer syndromes with high risk of endometrial and ovarian Cancer: Surgical options for personalized care.
- A phase II study of gemcitabine, carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian Cancer.
- Feasibility of Interval Cytoreduction Following Neoadjuvant Chemotherapy With Carboplatin, Weekly Paclitaxel, and Bevacizumab for Advanced Ovarian Cancer-A Phase 1 Study.
- DNA Damage-Binding Complex Recruits HDAC1 to Repress Bcl-2 Transcription in Human Ovarian Cancer Cells.
- Postoperative Outcomes among Patients Undergoing Thoracostomy Tube Placement at Time of Diaphragm Peritonectomy or Resection during Primary Cytoreductive Surgery for O...
- Reducing Readmissions after Robotic Surgical Management of Endometrial Cancer: A Potential for Improved Quality Care.
- Does adjuvant chemotherapy improve survival for women with early-stage Uterine leiomyosarcoma?
- Should bevacizumab be continued after progression on bevacizumab in recurrent ovarian Cancer?
- Multicenter phase II trial of topotecan, cisplatin and bevacizumab for recurrent or persistent Cervical cancer.
- Outcomes following percutaneous upper gastrointestinal decompressive tube placement for malignant bowel obstruction in ovarian Cancer.
- The impact of close surgical margins after radical hysterectomy for early-stage Cervical cancer.
- Complications After Double-Barreled Wet Colostomy Compared to Separate Urinary and Fecal Diversion During Pelvic Exenteration: Time to Change Back?
- HO-3867, a STAT3 inhibitor induces apoptosis by inactivation of STAT3 activity in BRCA1-mutated ovarian Cancer cells.
- The 2012 Annual Meeting on Women's Cancer.
- Phase I feasibility study of intraperitoneal cisplatin and intravenous paclitaxel followed by intraperitoneal paclitaxel in untreated ovarian, Fallopian tube, and prim...
- Addition of bevacizumab to weekly paclitaxel significantly improves progression-free survival in heavily pretreated recurrent epithelial ovarian Cancer.
- Identification of patient groups at highest risk from traditional approach to ovarian Cancer treatment.
- Surveillance for the detection of recurrent ovarian Cancer: survival impact or lead-time bias?
- Improved progression-free and overall survival in advanced ovarian Cancer as a result of a change in surgical paradigm.
- Incidence and management of pancreatic leaks after splenectomy with distal pancreatectomy performed during primary cytoreductive surgery for advanced Ovarian, peritone...
- A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced Ovarian, tubal and peritoneal ca...
- Upper abdominal surgical procedures: liver mobilization and diaphragm peritonectomy/resection, splenectomy, and distal pancreatectomy.
- The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, Fallopian tube, and primary peritone...
- The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian Cancer.
- Platinum resistance and impaired survival in patients with advanced primary peritoneal Carcinoma: matched-case comparison with patients with epithelial ovarian Carcinoma.
- Nomogram for survival after primary surgery for bulky stage IIIC ovarian Carcinoma.
- Prospective study of the correlation between postoperative computed tomography scan and primary surgeon assessment in patients with advanced Ovarian, tubal, and perito...
- A new frontier for quality of care in gynecologic oncology surgery: multi-institutional assessment of short-term outcomes for ovarian Cancer using a risk-adjusted model.
- Response and outcomes in elderly patients with stages IIIC-IV ovarian Cancer receiving platinum-taxane chemotherapy.
- Comparing surgical outcomes in obese women undergoing laparotomy, laparoscopy, or laparotomy with panniculectomy for the staging of Uterine malignancy.
- Delaying the primary surgical effort for advanced ovarian Cancer: a systematic review of neoadjuvant chemotherapy and interval cytoreduction.
- Liver mobilization and diaphragm peritonectomy/resection.
- Incidence and management of pleural effusions after diaphragm peritonectomy or resection for advanced mullerian Cancer.
- The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian Cancer.
- Identification of prognostic factors after positive second-look surgery in epithelial ovarian Carcinoma.
Schools
University Of California San Diego School Of Medicine
Procedures Preformed
- Colposcopy
- Destruction or Excision of Lesion of Cervix (incl. LEEP)
- Dilation and Curettage
- EndoCervical Curettage
- View All
Conditions Treated
- Atrophic Vaginitis
- Carcinoma in Situ
- Cervical Cancer
- Cervical Polyps
- View All
Doctors Specialties
- Obstetrics
- Gynecology
Accepted Insurances
Awards
- Regional Top Doctor
- CMS Meaningful Use Stage 1 Certification
Education
-
Memorial Sloan-Kettering Cancer Center -
Brigham and Women's Hospital -
Massachusetts General Hospital -
University of California San Diego School of Medicine
Hospital
-
University of Cincinnati Medical Center
Drug Facts
| NPI NUMBER | 1205001351 | |
| NPPES Provider LastName | EISENHAUER | |
| NPPES Provider FirstName | ERIC | |
| NPPES Provider ZIPCode | 452192364 | |
| NPPES Provider State | OH | |
| Specialty Description | Gynecological/Oncology | |
| Total Claim Count | 69.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1205001351 |
| Last Name Of The Provider | EISENHAUER |
| First Name Of The Provider | ERIC |
| View All |
Similar Doctors
|
Dr. Robert R. Flanagan, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Deanna D. Caminiti, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Joyce L. Horn, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Emily L. Wiebracht, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mounira A. Habli, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Deward H. Voss, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Sindura Bandi, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronald C. Merkel, MD
This Doctor is OpenDoctor Recommended.
|